David S Hong
M.D. Anderson Cancer Center
5
5
3
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Aung Naing, Md
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Vincent Chung
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Sriram Yennu
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Rahul Aggarwal, MD
University of California, San Francisco
Shared therapeutic areas:
Worked with same sponsors:
Virginia Sun
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Anurag K Singh
Roswell Park Cancer Institute
Shared therapeutic areas:
Worked with same sponsors:
A P Chen
National Cancer Institute LAO
Shared therapeutic areas:
Worked with same sponsors:
Heinz-Josef Lenz, MD
University of Southern California
Shared therapeutic areas:
Worked with same sponsors:
Zhongxing Liao, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
David Hui, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
All 5 trials loaded